Suchergebnisse - "Gong, Xiaodan"

PubPharm (12)

1

Meropenem for the Pharmacological Treatment of Severe Infections in Critically Ill Pediatric Patients : Breakthrough Standard Treatment Strategies Based on PK/PD

enthalten in: Current drug metabolism | 2023

von He, X. | Liu, X. | Gong, X. | +2

2

Recent progress in the mechanisms, preparations and applications of polymeric antifogging coatings

enthalten in: Advances in colloid and interface science | 2022

von Gong, X. | Yu, H. | Wang, L. | +4

3

Relationship of arterial tonometry and exercise in patients with chronic heart failure : a systematic review with meta-analysis and trial sequential analysis

enthalten in: BMC cardiovascular disorders | 2022

von Gong, X. | Hu, M. | Li, M.

4

Relationship of arterial tonometry and exercise in patients with chronic heart failure: a systematic review with meta-analysis and trial sequential analysis

enthalten in: BMC cardiovascular disorders | 2022

von Gong, X. | Hu, M. | Li, M.

5

Malignant Hyperthermia When Dantrolene Is Not Readily Available

enthalten in: ResearchSquare.com | 2022

von Gong, X.

6

Relationship of Arterial Tonometry and Exercise in Patients With Chronic Heart Failure: a Systematic Review With Meta-analysis and Trial Sequential Analysis

enthalten in: ResearchSquare.com | 2021

von Gong, X. | Hu, M. | Li, M. | +1

7

Malignant hyperthermia when dantrolene is not readily available

enthalten in: BMC anesthesiology | 2021

von Gong, X.

8

Malignant hyperthermia when dantrolene is not readily available

enthalten in: BMC anesthesiology | 2021

von Gong, X.

9

Multicolor and Multistage Response Electrochromic Color-Memory Wearable Smart Textile and Flexible Display

enthalten in: ACS applied materials & interfaces | 2021

von Wang, C. | Jiang, X. | Cui, P. | +4

10

Inhibition of gastric cancer by local anesthetic bupivacaine through multiple mechanisms independent of sodium channel blockade

enthalten in: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie | 2018

von Dan, J. | Gong, X. | Li, D. | +3